Journal
DRUG RESISTANCE UPDATES
Volume 10, Issue 3, Pages 109-120Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2007.03.001
Keywords
tumor vasculature; angiogenesis; interstitial fluid pressure; tumor blood flow heterogeneities; tumor-associated fibroblasts; tumor-associated macrophages; anti-angiogenic; vascular-disrupting agents; caveolae; transcytosis
Categories
Ask authors/readers for more resources
The identification of a critical role of tumour stroma in the regulation of tumour interstitial fluid pressure and the simultaneous discovery of the impact of anti-angiogenic drugs on tumour hemodynamics have provided new potential for improving tumour delivery of anti-cancer drugs. Here, we review the most recent studies investigating how tumour-associated fibroblasts and macrophages as well as the extracellular matrix itself may be targeted to facilitate delivery of both low-molecular weight drugs and macromolecules. In addition, we summarize the current understanding of the use of vasoactive compounds, radiotherapy and vascular-disrupting agents as potential adjuvants to maximize tumour delivery of anti-cancer drugs. The impact of these strategies on the diffusive and convective modes of drug transport is discussed in the light of Fick's and Starling's laws. Finally, we discuss how transcytosis through caveolae may also be exploited to optimize the selective delivery of conventional chemotherapy the subendothelial tumour cell compartment. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available